Ibrutinib
Brand name: Imbruvica
Rank #18 of 500 drugs by total cost
$875.8M
Total Cost
56,368
Total Claims
$875.8M
Total Cost
2,138
Prescribers
$16K
Cost per Claim
435
Beneficiaries
56,993
30-Day Fills
$410K
Avg Cost/Provider
26
Avg Claims/Provider
About Ibrutinib
Ibrutinib (sold as Imbruvica) was prescribed 56,368 times by 2,138 Medicare Part D providers in 2023, costing the program $875.8M. At $16K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 15 | Enzalutamide (Xtandi) | $985.0M | 72,710 |
| 16 | Mirabegron (Myrbetriq) | $927.5M | 1,407,073 |
| 17 | Tirzepatide (Mounjaro) | $877.9M | 680,457 |
| 18 | Ibrutinib (Imbruvica) | $875.8M | 56,368 |
| 19 | Ustekinumab (Stelara) | $852.3M | 31,974 |
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology